TORRANCE, Calif., May 13, 2022 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update.
Recent Highlights
- April 2022: Announced the launch of an innovative, full-service telehealth solution (https://www.endarirx.com/ask-physician) with…
